China's Sinovac Biotech Ltd launched on Tuesday a late-stage human trial involving as many as 1,620 patients in Indonesia for a COVID-19 vaccine candidate that it is developing with Indonesian state-owned peer Bio Farma.
JAKARTA/BEIJING - China’s Sinovac Biotech Ltd launched on Tuesday a late-stage human trial involving as many as 1,620 patients in Indonesia for a COVID-19 vaccine candidate that it is developing with Indonesian state-owned peer Bio Farma.
The candidate, known as CoronaVac and previously PiCoVacc, is among few potential vaccines that have entered late-stage trials for a large-scale study to gather proof of efficacy for regulatory approval.Its Indonesia trial comes as Southeast Asia’s most populous country grapples with spiking infection numbers, with over 127,000 cases recorded as of Tuesday. The trial has so far recruited 1,215 people and will last six months.
Separately, Sinovac late on Monday released details from a mid-stage, or Phase 2, study in which it said the vaccine candidate appeared to be safe and induced detectable antibody-based immune responses in subjects.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
China's Sinopharm starts Phase III trial of COVID-19 vaccine in BahrainChinese state-owned pharmaceutical company Sinopharm has begun Phase III clinical trials of a COVID-19 vaccine in Bahrain, after launching similar trials in the United Arab Emirates last month, Bahrain's health ministry said on Monday.
Weiterlesen »
Russia chooses less testing, faster production to win COVID-19 vaccine raceThe Russian team hopes to start mass production of its vaccine in October, far sooner than other leading scientists.
Weiterlesen »
Saudi Arabia to begin human trials with CanSino's Covid-19 vaccineResearchers say CanSino's vaccine which is co-developed with China's military research unit, appears to be safe and induced immune responses in most subjects.
Weiterlesen »
Goldman Sachs lifts 2021 US GDP forecast to 6.2% and predicts a COVID-19 vaccine will be 'widely distributed' by mid-2021 | Markets InsiderGoldman Sachs raised its 2021 US GDP forecast to 6.2% from 5.6%, driven by expectations that at least one COVID-19 vaccine will be 'widely distr...
Weiterlesen »
A letter from Chennai as India tops 2 million COVID-19 cases: ‘In the midst of so much death, despair and depression, life does go on’India has topped 2 million COVID-19 cases. Our report from Chennai, India shows the lockdown in March and the economic impact have hit the poorest Indians the hardest. 'In the midst of so much death, despair and depression, life does go on.'
Weiterlesen »
Suns' Deandre Ayton Races to Join Team Mid-Game After Late COVID-19 TestPhoenix Suns center Deandre Ayton just rushed to join his team mid-game against the OKC Thunder on Monday ... after the 22-year-old got a last-minute COVID-19 test.
Weiterlesen »